Search results for "PROTEINE"

showing 10 items of 179 documents

Familial hypercholesterolaemia: A global call to arms

2015

Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited condition affecting man. It is caused by mutation in one of three genes, encoding the low-density lipoprotein (LDL) receptor, or the gene for apolipoprotein B (which is the major protein component of the LDL particle), or in the gene coding for PCSK9 (which is involved in the degradation of the LDL-receptor during its cellular recycling). These mutations result in impaired LDL metabolism, leading to life-long elevations in LDL-cholesterol (LDL-C) and development of premature atherosclerotic cardiovascular disease (ASCVD) [1], [2] and [3]. If left untreated, the relative risk of premature coronary artery d…

PathologyApolipoprotein BDisease030204 cardiovascular system & hematologymedicine.disease_causeGlobal HealthDISEASEDoenças Cardio e Cérebro-vasculares0302 clinical medicineHyperlipoproteinemia Type IISocieties MedicalRISK0303 health sciencesMutationbiology3. Good healthPREVALENCEEuropelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFamilial hypercholesterolaemiaLife Sciences & Biomedicinemedicine.medical_specialtyHeterozygote1102 Cardiovascular Medicine And HaematologyHyperlipoproteinemia Type II03 medical and health sciencesInternal medicinemedicineHumans030304 developmental biologyScience & Technologybusiness.industryGUIDANCEPCSK9Heterozygote advantage1103 Clinical SciencesEndocrinologyPeripheral Vascular DiseaseCardiovascular System & HematologyReceptors LDLRECEPTORES DE LIPOPROTEÍNASRelative riskMutationbiology.proteinCardiovascular System & CardiologyFamilial HypercholesterolaemiabusinessCLINICIANLipoprotein
researchProduct

Clinical disorders responsible for plasma hyperviscosity and skin complications

2017

In this brief review, we have examined some clinical disorders which are associated to an altered hemorheological profile and at times accompanied by skin ulcers. This skin condition may be, in fact, observed in patients with primary plasma hyperviscosity such as multiple myeloma, Waldenstrom macroglobulinemia, cryoglobulinemia, cryofibrinogenemia, dysfibrinogenemia and connective tissue diseases. It must be underlined that the altered hemorheological pattern is not the only responsible for this skin complication but, as it worsens the microcirculatory flow, it contributes to determine the occurrence of the skin ulcers.

Pathologymedicine.medical_specialtyParaproteinemiasCryofibrinogenemiaHyperviscosityConnective tissuePlasma hyperviscosity030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesWhole-blood viscositySkin UlcerInternal MedicinemedicineHumansDysfibrinogenemiaConnective Tissue DiseasesMultiple myeloma030203 arthritis & rheumatologyintegumentary systembusiness.industryMicrocirculationDisease ManagementWaldenstrom macroglobulinemiaSyndromeBlood Viscositymedicine.diseaseCryoglobulinemiaDermatologymedicine.anatomical_structureCryoglobulinemiaWaldenstrom MacroglobulinemiaMultiple MyelomaComplicationbusinessEuropean Journal of Internal Medicine
researchProduct

Total plasma protein in very preterm babies: prognostic value and comparison with illness severity scores

2013

International audience; OBJECTIVE: We aimed to investigate the predictive value for severe adverse outcome of plasma protein measurements on day one of life in very preterm infants and to compare total plasma protein levels with the validated illness severity scores CRIB, CRIB-II, SNAP-II and SNAPPE-II, regarding their predictive ability for severe adverse outcome. METHODS: We analyzed a cohort of infants born at 24-31 weeks gestation, admitted to the tertiary intensive care unit of a university hospital over 10.5 years. The outcome measure was "severe adverse outcome" defined as death before discharge or severe neurological injury on cranial ultrasound. The adjusted odd ratio (aOR) and 95%…

PediatricsMultivariate analysisCritical Care and Emergency MedicineEpidemiology[ SDV.MHEP.PED ] Life Sciences [q-bio]/Human health and pathology/Pediatricslcsh:MedicinePediatricslaw.inventionCohort Studies0302 clinical medicinelawInfant Very Low Birth Weight030212 general & internal medicineProspective StudiesPediatric Epidemiologylcsh:ScienceMultidisciplinaryArea under the curveBlood ProteinsIntensive care unit3. Good healthCohortMedicineInfant PrematureResearch Articlemedicine.medical_specialtyPediatric Critical CareClinical Research DesignBirth weightFluid Management03 medical and health sciencesHypoproteinemia030225 pediatricsInternal medicinemedicineHumansPrematureRetrospective StudiesNutrition[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsReceiver operating characteristicbusiness.industryVery Low Birth Weightlcsh:RInfant NewbornInfantmedicine.diseaseNewbornConfidence intervallcsh:QNeonatologybusiness
researchProduct

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

2019

Purpose of Review Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With “central support,” more centers and countries participated in the project. Subsequently, individ…

Pediatricsmedicine.medical_specialtyInternational CooperationFamilial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyTreatment resultsAntibodies Monoclonal HumanizedFHHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineTotal cholesterolmedicineHumansMass ScreeningEffective treatment030212 general & internal medicineScreenPro FHLDL-CAlirocumabInternational networkEvidence-Based Medicine Clinical Trials and Their Interpretations (L. Roever Section Editor)business.industryAnticholesteremic AgentsIncidencePCSK9 InhibitorsScreen and treatmedicine.diseaseEvolocumab3. Good healthEuropeEvolocumabProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessDelivery of Health CareAlirocumabCurrent Atherosclerosis Reports
researchProduct

Regulatory evaluation of Glybera in Europe — two committees, one mission

2013

Representing the first gene therapy to be approved in the Western world, alipogene tiparvovec (Glybera; Uniqure) has recently been said to have had a “substantial impact from a regulatory perspective” (Nature Rev. Drug Discov. 11, 664; 2012) 1 . The therapy was granted marketing authorization in the European Union for the treatment of lipoprotein lipase deficiency, which results in a clinically heterogeneous condition with a risk of potentially life-threatening pancreatitis 2 , at the end of 2012. The decision followed a positive opinion by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) 3

Pharmacologymedicine.medical_specialtybusiness.industryGenetic TherapyGeneral MedicineMarketing authorizationBiotechnologyAlipogene tiparvovecHuman useFamily medicineDrug DiscoveryAgency (sociology)Drug approvalHumansMedicineWestern worldmedia_common.cataloged_instanceHyperlipoproteinemia Type IEuropean UnionCooperative behaviorCooperative BehaviorEuropean unionbusinessDrug Approvalmedia_commonNature Reviews Drug Discovery
researchProduct

Observing heme doming in myoglobin with femtosecond X-ray absorption spectroscopy.

2015

International audience; We report time-resolved X-ray absorption measurements after photolysis of carbonmonoxy myoglobin performed at the LCLS X-ray free electron laser with nearly 100 fs (FWHM) time resolution. Data at the Fe K-edge reveal that the photoinduced structural changes at the heme occur in two steps, with a faster (∼70 fs) relaxation preceding a slower (∼400 fs) one. We tentatively attribute the first relaxation to a structural rearrangement induced by photolysis involving essentially only the heme chromophore and the second relaxation to a residual Fe motion out of the heme plane that is coupled to the displacement of myoglobin F-helix

PhotodissociationAbsorption spectroscopyTime resolved spectroscopyInvited ArticlesPhotochemistrySPECIAL TOPIC: BIOLOGY WITH X-RAY LASERS 2chemistry.chemical_compoundX-ray absorption spectralcsh:QD901-999X-ray absorption near edge structureSpectroscopyInstrumentationHemeSpectroscopy[PHYS]Physics [physics]RadiationX-ray optics[SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry Molecular Biology/Structural Biology [q-bio.BM]ChemistryPhotodissociationRelaxation (NMR)ChromophoreCondensed Matter PhysicsSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)MyoglobinBiofisica Dinamica delle proteine Spettroscopia risolta in tempo X-ray free-electron laser Assorbimento di raggi Xlcsh:CrystallographyTime-resolved spectroscopyStructural dynamics (Melville, N.Y.)
researchProduct

Lecithin-cholesterol-acyltransferase deficiency: autosomal recessive transmission in a large kindred.

2008

Thirty-four members of a single Sardinian kindred with lecithin-cholesterol-acyltransferase deficiency have been studied. The kindred spans four generations and the parents of the two affected siblings are blood relatives. Segregation of the acyltransferase deficiency gene in the family clearly demonstrated an autosomal recessive mode of inheritance. Thirteen family members, including all obligate heterozygotes, had roughly half-normal acyltransferase activities (mean +/- S.D. = 0.39 +/- 0.06 mU/ml) when compared to 17 intrafamilial controls and spouses (mean +/- S.D. = 0.72 +/- 0.09 mU/ml) and 40 blood donors from Marburg/Lahn (mean +/- S.D. =0.76 +/- 0.1 mU/ml). Characterization of the he…

Plasma lipoproteinMaleHeterozygoteThalassemiaLipoproteinsGenes RecessiveConsanguinityConsanguinityLecithin Cholesterol Acyltransferase DeficiencyGeneticsmedicineHumansGenetics (clinical)GeneticsLecithin cholesterol acyltransferase deficiencybiologyHeterozygote advantagemedicine.diseaseHypolipoproteinemiasPedigreeAcyltransferaseLecithin—cholesterol acyltransferasebiology.proteinThalassemiaFemaleHypolipoproteinemiaClinical genetics
researchProduct

Effectiveness of screening for known mutations in Sicilian patients with "probable" familial hypercholesterolemia.

2002

Background and Aim: More than 750 mutations in the low-density lipoprotein (LDL) receptor gene are currently known to cause familial hypercholesterolemia (FH), but the array of mutations varies considerably in different populations. The definition of essentially all the LDL receptor gene mutations in a population is therefore a prerequisite for the implementation of nation-wide genetic testing for FH. Methods and Results: In this study, a screening strategy based on PCR-enzymatic digestion and PCR-allele specific hybridisation procedures was used to evaluate the frequency distributions of 11 known mutations in a cohort of 214 unrelated subjects meeting the diagnostic criteria of "probable" …

Point mutationNutrition and DieteticsSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)ExonsPolymerase Chain ReactionFHCohort StudiesHyperlipoproteinemia Type IIGene FrequencyReceptors LDLMutationScreeningHumansGenetic TestingCardiology and Cardiovascular MedicineSicilyFood Science
researchProduct

GENETIC MARKERS OF DEVELOPMENT AND PROGRESSION OF THE ATHEROSCLEROSIS. POSSIBLE ROLE OF VARIANTS THAT CHANGE THE INTERACTIONS WITH THE PROTEOGLYCANS …

2021

Polygenic diseaseFamilial HypercholesterolemiaMonogenic diseaseCoronary artery diseaseFamilial Hypobetalipoproteinemia
researchProduct

Comparison of two polygenic risk score to identify non-monogenic primary hypocholesterolemias in a large cohort of Italian hypocholesterolemic subjec…

2022

Background: Primary Hypobetalipoproteinemias (HBL) are a group of dominant and recessive monogenic genetic disorders caused by mutations in APOB, PCSK9, ANGPTL3, MTTP, Sar1b genes and characterized by plasma levels of total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) below the 5th percentile of the distribution in a given population. Mutations in the candidate genes account only for a small proportion of subjects with HBL suggesting a role for a polygenic contribution to the low cholesterol phenotype. Objective: To explore the complex genetic architecture of HBL we compared two polygenic risk scores in order to assess the role of the polygenic b…

Polygenic risk scoreMutationHypobetalipoproteinemia
researchProduct